Literature DB >> 183554

Double-blind test of metronidazole and tinidazole in the treatment of asymptomatic Entamoeba histolytica and Entamoeba hartmanni carriers.

R Spillmann, S C Ayala, C E Sanchez.   

Abstract

One hundred and fifteen persons with asymptomatic Entamoeba histolytica or E. hartmanni infection, or both, were given metronidazole (750 mg three times daily for 5 days), tinidazole (1 g twice daily on 2 consecutive days), or a starch placebo. Three post-treatment stools were examined in the 2 weeks following initiation of treatment. Cysts of E. histolytica reappeared in the stools of 37% of 30 given metronidazole, 62% of 34 given tinidazole, and 70% of 31 given placebo. Cysts of E. hartmanni reappeared in the stools of 46% of 24 given metronidazole, 69% of 16 given tinidazole, and 90% of 10 given placebo. Rapid absorption and short duration of treatment make both drugs ineffective for the treatment of ameba carriers.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 183554     DOI: 10.4269/ajtmh.1976.25.549

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  4 in total

1.  Progress report intestinal protozoa.

Authors:  R Knight; S G Wright
Journal:  Gut       Date:  1978-10       Impact factor: 23.059

2.  Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples.

Authors:  Joerg Blessmann; Heidrun Buss; Phuong A Ton Nu; Binh T Dinh; Quynh T Viet Ngo; An Le Van; Mohamed D Abd Alla; Terry F H G Jackson; Jonathan I Ravdin; Egbert Tannich
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

3.  In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole.

Authors:  J I Ravdin; J Skilogiannis
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

4.  Antiamoebic drugs for treating amoebic colitis.

Authors:  Maria Liza M Gonzales; Leonila F Dans; Juliet Sio-Aguilar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.